Nasdaq
$11.14▼ 0.58%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.56BShares out 1.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.6After-hours26.10.07 05:054Ownership#●●●
Intellia Therapeutics, Inc.
Michael P. Dube, an executive at Intellia Therapeutics, Inc., filed a Form 4 report regarding changes in his beneficial ownership of company securities as of October 2, 2026. This filing serves as an official disclosure of insider stock holdings activity.…more
$11.14-0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:45144Ownership
Intellia Therapeutics, Inc.
Eliana Clark, an executive at Intellia Therapeutics, Inc., has filed an SEC Form 144 to report the proposed sale of company stock. This filing represents a routine disclosure of an insider's plan to dispose of shares.…more
$11.14-0.58%vs prev closeView filingShare - 9.8After-hours26.09.09 05:058-KKey event
Intellia Therapeutics, Inc.
Intellia Therapeutics announced that the FDA has accepted the Biologics License Application (BLA) for its hereditary angioedema (HAE) treatment, 'lonvo-z,' and granted it Priority Review. The FDA has set a PDUFA target action date of March 10, 2027, and currently does not plan to hold an advisory committee meeting.…more
$11.14-0.58%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:30#●●●#●●●
Intellia Therapeutics Appoints Jing L. Marantz as Chief Medical Officer…more
Intellia Therapeutics has appointed Dr. Jing L. Marantz, an expert in rare disease drug development, as its new Chief Medical Officer. This leadership change is aimed at accelerating the commercialization of the company's gene editing therapies and expanding its clinical pipeline.…more
$11.14-0.58%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.2After-hours26.10.03 05:01
●●●●●●●● ●●●●● ●●●●●●
Intellia Therapeutics has granted 44,450 restricted stock units (RSUs) to eight new employees as a material inducement for their employment. These grants were issued in accordance with Nasdaq Listing Rule 5635(c)(4) to attract new talent.…more
$11.14-0.58%vs prev close - 9.8Pre-market26.09.08 21:07
●●●●●●●● ●●●●● ●●●●●●
Intellia Therapeutics' Biologics License Application for its CRISPR-based therapy, Ionvo-Z, has been accepted by the FDA with Priority Review. The FDA has set a PDUFA target date of March 10, 2027, and currently does not plan to hold an advisory committee meeting.…more
$11.14-0.58%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report